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LETTERS
zoonotic; cats are primary reservoirs, 
and humans and dogs are accidental 
hosts (1). However, B. clarridgeiae 
was recently detected in rodent fleas 
in China (9) and B. koehlerae was iso-
lated from feral pigs from the south-
eastern United States (10), suggesting 
that these pathogens also have multiple 
reservoir species.
Clarifying whether Bartonella 
infections in raccoons are caused 
by spillover from feral cats needs 
further study. Additional samples 
from raccoons and other species in 
urbanized and undeveloped habitats 
with different host species compo-
sition (e.g., cat-free environment) 
might enable further Bartonella spp. 
characterization in wildlife. We sus-
pect urban raccoons and feral cats 
play a major role in Bartonella spp. 
transmission.
Acknowledgments
We thank Michael Yabsley, Barbara 
Shock, Matthew Stuckey, and Bruno 
Chomel for providing technical advice; 
and Mark Heth, Jan Rossiter and staff at 
the Island Animal Hospital, St. Simons Is-
land, Georgia, for assistance with sample 
collection.
This study was supported by the St. 
Catherines Island Foundation, Inc., and 
Odum School of Ecology, University of 
Georgia, through the course taught by Van-
essa Ezenwa and Andrew Park (ECOL/
IDIS 8150L).
Jusun Hwang and  
Nicole L. Gottdenker




  1. Chomel BB, Boulouis HJ, Breitschwerdt 
EB, Kasten RW, Vayssier-Taussat M, 
Birtles RJ, et al. Ecological fitness and 
strategies of adaptation of Bartonella 
species to their hosts and vectors. Vet Res. 
2009;40:29. http://dx.doi.org/10.1051/ 
vetres/2009011
  2. Kosoy M, Hayman DT, Chan KS. Barton-
ella bacteria in nature: where does popula-
tion variability end and a species start? In-
fect Genet Evol. 2012;12:894–904. http://
dx.doi.org/10.1016/j.meegid.2012.03.005
  3. Kosoy MY. Ecological associations 
between bacteria of the genus Barton-
ella and mammals. Biological Bul-
letin. 2010;37:716–24. http://dx.doi.
org/10.1134/S1062359010070071
  4. Trataris AN, Rossouw J, Arntzen L, 
Karstaedt A, Frean J. Bartonella spp. 
in human and animal populations in 
Gauteng, South Africa, from 2007 to 2009. 
Onderstepoort J Vet Res. 2012;79:E1–8. 
http://dx.doi.org/10.4102/ojvr.v79i2.452
  5. Roux V, Raoult D. The 16S–23S rRNA 
intergenic spacer region of Bartonella 
(Rochalimaea) species is longer than 
usually described in other bacteria. 
Gene. 1995;156:107–11. http://dx.doi.
org/10.1016/0378-1119(94)00919-J
  6. Thompson JD, Higgins DG, Gibson TJ. 
CLUSTAL W: improving the sensitiv-
ity of progressive multiple sequence 
alignment through sequence weight-
ing, position-specific gap penalties and 
weight matrix choice. Nucleic Acids 
Res. 1994;22:4673–80. http://dx.doi.
org/10.1093/nar/22.22.4673
  7. Tamura K, Peterson D, Peterson N, 
Stecher G, Nei M, Kumar S. MEGA5: 
molecular evolutionary genetics analysis 
using maximum likelihood, evolution-
ary distance, and maximum parsimony 
methods. Mol Biol Evol. 2011;28:2731–9. 
http://dx.doi.org/10.1093/molbev/msr121
  8. Henn JB, Chomel BB, Boulouis HJ, 
Kasten RW, Murray WJ, Bar-Gal 
GK, et al. Bartonella rochaelimae in 
raccoons, coyotes, and red foxes. Emerg 
Infect Dis. 2009;15:1984–7. http://dx.doi.
org/10.3201/eid1512.081692
  9. Li DM, Liu QY, Yu DZ, Zhang JZ, Gong 
ZD, Song XP. Phylogenetic analysis of 
Bartonella detected in rodent fleas in Yun-
nan, China. J Wildl Dis. 2007;43:609–17.
10. Beard AW, Maggi RG, Kennedy-Stoskopf 
S, Cherry NA, Sandfoss MR, DePerno CS, 
et al. Bartonella spp. in feral pigs, south-
eastern United States. Emerg Infect Dis. 
2011;17:893–5. http://dx.doi.org/10.3201/
eid1705.100141
Address for correspondence: Nicole Gottdenker, 
Department of Veterinary Pathology, College 
of Veterinary Medicine, University of Georgia, 





Disease in  
HIV-Infected Infant, 
Vietnam
To the Editor: Guidelines for the 
diagnosis and management of Myco-
bacterium bovis BCG disease in HIV-
infected children are lacking. BCG 
strains are intrinsically resistant to 
pyrazinamide and in some cases have 
low-level resistance to isoniazid (6). 
However, data on acquired drug resis-
tance in M. bovis BCG are limited. We 
describe a case of BCG disease caused 
by a rifampin-resistant strain of M. 
bovis BCG in an HIV-infected infant 
in Vietnam.
The daughter of a known HIV-
infected woman, who did not fully 
adhere to antiretroviral therapy (ART) 
during pregnancy, received the M. bo-
vis intradermal BCG (Pasteur strain) 
vaccine at birth. HIV infection was 
diagnosed in the infant by PCR when 
she was 8 weeks of age. At 9 months 
of age, she was admitted to the Pedi-
atric Infectious Diseases Department 
of the Pham Ngoc Thach Hospital (Ho 
Chi Minh City, Vietnam) because of a 
voluminous ipsilateral axillary mass 
at the site of the vaccination, fever, 
weight loss, and hepatosplenomegaly. 
The percentage of CD4+ T cells was 
27% (1,620 cells/mm3). Regional BCG 
disease was clinically diagnosed with-
out microbiological investigation, and 
a broad antimycobacterial therapy tar-
geting M. tuberculosis complex species 
was started with 5 mg/kg isoniazid, 10 
mg/kg rifampin, and 25 mg/kg pyrazin-
amide. After 6 weeks of antimycobac-
terial therapy, ART was initiated with 
lamivudine, stavudine, and abacavir. 
After 6 months of antimycobac-
terial treatment, the infant was hospi-
talized again for recurrent inflamma-
tion and fistulization of the axillary 
lymph nodes associated with fever. 
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Fluid from the axillary mass was col-
lected by fine-needle aspiration for 
bacteriologic investigations. Direct 
microscopic examination showed ac-
id-fast bacilli, and the mycobacterial 
infection was confirmed by culture. 
By using conventional biochemical 
methods, the mycobacterial isolate 
was assigned to the M. bovis species. 
Pyrazinamide was discontinued, and 
antimycobacterial therapy was con-
tinued for 4 supplementary months 
with rifampin (15 mg/kg) and iso-
niazid (10 mg/kg). After 2 months, 
drug susceptibility testing results 
confirmed pyrazinamide intrinsic re-
sistance and isoniazid and ethambutol 
susceptibility and showed rifampin 
resistance. The late inflammatory 
reaction after introduction of ART 
was evocative of immune reconsti-
tution inflammatory syndrome. Nev-
ertheless, drug resistance may have 
contributed. Despite the rifampin 
resistance, the patient showed clini-
cal improvement, and the rifampin/
isoniazid treatment was continued for 
2 more months. The child’s BCG dis-
ease was cured on completion of 10 
months of antituberculous treatment.
Retrospective molecular inves-
tigations using the GenoType MTBC 
Kit (Hain Lifescience, Nehren, Ger-
many) enabled identification of the 
isolate stored at −80°C as M. bovis 
BCG strain. A mutation in the rpoB 
gene (codon 531, Ser531Tyr) asso-
ciated with rifampin resistance was 
detected by using the GenoType MT-
BDRplus Kit (Hain Lifescience) and 
partial sequencing of the rpoB gene 
(5,7). No mutation in the katG and 
inhA genes, frequently associated with 
isoniazid resistance, was detected.
To our knowledge, this case is the 
second report of rifampin-resistant M. 
bovis BCG disease in HIV-infected 
children. The first report involved a 
child in South Africa who was vac-
cinated with the Danish BCG strain 
(4); this strain shows low-level resis-
tance to isoniazid and therefore has 
a high risk of evolving to multidrug 
resistance in instances of suboptimal 
isoniazid levels. The M. bovis BCG 
Pasteur strain (American Type Culture 
Collection 35734) used for vaccina-
tion in Vietnam is isoniazid and ri-
fampin susceptible and pyrazinamide 
resistant (9). Despite appropriate anti-
mycobacterial treatment, the relative-
ly low doses of isoniazid (5 mg/kg), 
poor adherence, or inadequate absorp-
tion of drugs because of HIV-related 
gastrointestinal disease may have re-
sulted in subtherapeutic in vivo drug 
concentrations and thus in selection of 
a drug-resistant M. bovis BCG strain. 
This case should alert clinicians of the 
possible emergence of rifampin resis-
tant M. bovis BCG strains.
Because disseminated BCG dis-
ease in HIV-infected children pres-
ents a high risk for illness and/or 
death, these patients should receive 
optimal tuberculosis treatment (2) 
based on 4-drug (rifampin, isonia-
zid, ethambutol, and pyrazinamide) 
regimen doses for at least 9 months 
until M. tuberculosis is ruled out (3). 
Untreated local BCG immune recon-
stitution inflammatory syndrome may 
not necessarily progress to dissemi-
nation; therefore, treatment would 
not appear necessary (8).
Some studies suggest that the sur-
vival of HIV-infected children with 
BCG disease could be attributed to 
early initiation of ART in combina-
tion with other treatments (1,3). In 
the South Africa case, the child died, 
and the authors suggested that this 
outcome was related to the sever-
ity of the clinical features, the severe 
HIV-related immune suppression, and 
the absence of ART (4). In the case 
in Vietnam, despite the emergence of 
drug resistance, the early initiation of 
ART in a child with a localized dis-
ease, the persistent efficacy of isonia-
zid, and the spontaneous fistulization 
of the abscess probably contributed to 
the good outcome for the infant.
In conclusion, this case highlights 
the challenges in management of BCG 
disease in children. It also emphasizes 
the possible risk for emergence of 
acquired drug resistance in M. bovis 
BCG strains, complicating the medical 
management of such cases.
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To the Editor: Bulleidia extructa 
is an obligately anaerobic, nonmo-
tile, non–spore-forming gram-positive 
bacillus first described in 2000 by 
Downes et al. (1), after having iso-
lated a bacterium from the oral cavity 
of persons with periodontitis and den-
toalveolar abscesses that did not cor-
respond to any known species. After 
phenotypic and genetic characteriza-
tion, the investigators proposed a new 
genus, Bulleidia, and the species B. 
extructa. Since then, additional reports 
have associated the organism with oral 
infections, specifically periodontal 
disease (2–5). While B. extructa’s as-
sociation with human periodontal dis-
ease is well documented, the bacterium 
has so far not been implicated in other 
pathogenic processes. We report here a 
case of a total hip arthroplasty infection 
caused by B. extructa in an immuno-
competent patient.
In November 2010, an 82-year-
old man with a non-cemented right 
total hip arthroplasty that was per-
formed 26 years previously was evalu-
ated for right hip pain. He had been in 
his usual state of health without any 
complaints until a month earlier, when 
he lost his footing and hyperabducted 
his hip joints, involuntarily perform-
ing a split, while washing a boat cover 
with a power washer. Since then, he 
reported right hip pain that somewhat 
limited his mobility.
Physical examination revealed an 
antalgic gait, mild swelling of the right 
lower extremity, and impaired hip mo-
bility related to pain on the right side, 
specifically with extension, flexion, 
abduction, and adduction. Results of 
the patient’s blood work were notable 
for normocytic anemia (hemoglobin 
10.6 g/dL), thrombocytosis (459 × 
109/L), elevated erythrocyte sedimen-
tation rate (101 mm/h), and elevated 
C-reactive protein (88.7 mg/L). Leu-
kocyte count was within normal limits 
(9.6 × 109 cells/L). An ultrasound ex-
amination of the right hip joint showed 
extensive synovitis and a large, 4.3 × 
5.0 × 5.1–cm vascular mass extending 
anteriorly from the joint space. Aspira-
tion of the joint space yielded 1 mL of 
blood-stained fluid with 111,595 cells/
µL (95% neutrophils, 5% monocytes/ 
macrophages). Anaerobic bacterial 
culture grew a gram-positive bacil-
lus identified as B. extructa by partial 
16S rRNA sequencing. DNA was pre-
pared for PCR amplification by using 
PrepMan Ultra (Applied Biosystems, 
Foster City, CA, USA) and ampli-




generated 484-bp sequence differed 
by 2 bp from 483 bp of available se-
quence from B. extructa GenBank ac-
cession no. AF220064. The isolate was 
susceptible to penicillin, clindamycin, 
and metronidazole by using E-test.
The patient underwent total hip 
arthroplasty resection. Intraoperative-
ly, purulence was noted upon enter-
ing the hip joint. Histopathologic ex-
amination of removed tissue revealed 
acute inflammation. Five hip tissue 
specimens were obtained for culture; 
3 specimens yielded B. extructa. Six 
weeks of intravenous ceftriaxone 
treatment was prescribed, and the pa-
tient was instructed to revisit a dentist 
for a full dental examination. Before 
seeking treatment for this episode, he 
reported that he was seeing a dentist 
on a regular basis and denied any re-
cent dental surgery or infections.
The patient was seen in a follow-
up visit 2 months after reimplantation 
surgery; at that time, he reported mini-
mal pain and had begun to bear weight 
on the affected side. There was no evi-
dence for infection recurrence.
Periprosthetic joint infections are 
a major complication after joint re-
placement. The number of procedures 
for total hip and knee replacements has 
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